GB2622880A — Palatable orodispersible formulation of vortioxetine
Assigned to Alkaloid AD Skopje · Expires 2024-04-03 · 2y expired
What this patent protects
A novel orodispersible formulation of vortioxetine is disclosed comprising a granular component, a polymeric component and an extragranular matrix. Methods of preparing such a formulation and the use of such a formulation in a method of treatment of a patient are also disclosed. …
USPTO Abstract
A novel orodispersible formulation of vortioxetine is disclosed comprising a granular component, a polymeric component and an extragranular matrix. Methods of preparing such a formulation and the use of such a formulation in a method of treatment of a patient are also disclosed. The method of treatment involves direct administration of the orodispersible formulation to the oral mucosa and allowing the formulation to dissolve.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.